Muscular Dystrophy Canada (MDC) is deeply disappointed with CADTH’s final recommendation against reimbursement and access to potentially life-changing treatment for adults affected by spinal muscular atrophy.
“It is extremely challenging for patients not to have access to treatments in Canada when real-world evidence shows a treatment can be beneficial,” said Stacey Lintern, CEO, Muscular Dystrophy Canada. “While this is not the news we were hoping for, MDC is as committed as ever to breaking down barriers for all Canadians affected by neuromuscular disorders,” “We will continue to advocate and work with government and other like-minded organizations, to influence policy and processes so the neuromuscular community has access to treatments and can make informed decisions concerning treatment options.”
